CytoDyn

CytoDyn is a privately held company based in Vancouver, Washington, with 19 employees. CytoDyn is focused on late-stage clinical development of leronlimab, a CCR5 receptor antagonist, for use as a platform drug across various therapeutic areas. These areas include non-alcoholic steatohepatitis (NASH), NASH in combination with HIV, oncology, and HIV. Leronlimab is a humanized monoclonal antibody delivered as a weekly subcutaneous injection and can also be administered intravenously. It acts by competitively binding to the CCR5 receptor, a protein found on various cells involved in immune response, scar tissue production in the liver, and malignant cell transformation. Leronlimab's competitive inhibition of the CCR5 receptor distinguishes it from other CCR5 antagonists. This mechanism of action is believed to have implications for treating a range of conditions. For more information about CytoDyn and leronlimab, please visit cytodyn.com.